Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226

Biochemical Pharmacology

Volumn 75, Issue 2, 2008, Pages 360-368

  Chen, Chun Jen ^a   Hsu, Mei Hua ^a   Huang, Li Jiau ^a   Yamori, Takao ^b   Chung, Jing Gung ^a   Lee, Fang Yu ^c   Teng, Che Ming ^d   Kuo, Sheng Chu ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c Yung Shin Pharmaceutical Industry Co Ltd   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anti metastasis; Apoptosis; Cell cycle arrest; NCI H226; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; GELATINASE A; GELATINASE B; PROTEIN P16; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CENTER; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG CANCER; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE; HUMANS; INDAZOLES; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM METASTASIS;

EID: 37349002494     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.011     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 55 (2005) 106-130
2. Department of Health. Vital Statistics, 2004 (2005), Department of Health, Taipei
3. Sawyers C. Targeted cancer therapy. Nature 432 (2004) 294-297
4. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., and Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 84 (1994) 4226-4233
5. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., and Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116 (1995) 1973-1978
6. Teng C.M., Wu C.C., Ko F.N., Lee F.Y., and Kuo S.C. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 320 (1997) 161-166
7. Friebe A., Schultz G., and Koesling D. Stimulation of soluble guanylate cyclase by superoxide dismutase is mediated by NO. Biochem J 335 (1998) 527-531
8. Chun Y.S., Yeo E.J., and Park J.W. Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett 207 (2004) 1-7
9. Wang S.W., Pan S.L., Guh J.H., Chen H.L., Huang D.M., Chang Y.L., et al. YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 312 (2005) 917-925
10. Yeo E.J., Ryu J.H., Chun Y.S., Cho Y.S., Jang I.J., Cho H., et al. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res 66 (2006) 6345-6352
11. Pan S.L., Guh J.H., Peng C.Y., Wang S.W., Chang Y.L., Cheng F.C., et al. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharmacol Exp Ther 314 (2005) 35-42
12. Pan S.L., Guh J.H., Peng C.Y., Chang Y.L., Cheng F.C., Chang J.H., et al. A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb Haemost 93 (2005) 940-948
13. Liu Y.N., Pan S.L., Peng C.Y., Guh J.H., Huang D.M., Chang Y.L., et al. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metal-oproteinases 2 and 9. J Pharmacol Exp Ther 316 (2006) 35-41
14. Huang Y.T., Pan S.L., Guh J.H., Chang Y.L., Lee F.Y., Kuo S.C., et al. YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 4 (2005) 1628-1635
15. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81 (1989) 1088-1092
16. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83 (1991) 757-766
17. Yamori T., Matsunaga A., Sato S., Yamazaki K., Komi A., Ishizu K., et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 59 (1999) 4042-4049
18. Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol 52 1 (2003) S74-S79
19. English J., Pearson G., Wilsbacher J., Swantek J., Karandikar M., Xu S., et al. New insights into the control of MAP kinase pathways. Exp Cell Res 253 (1999) 255-270
20. Herr I., and Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 98 (2001) 2603-2614
21. Ruvolo P.P., Deng X., and May W.S. Phosphorylation of Bcl-2 and regulation of apoptosis. Leukemia 15 (2001) 515-522
22. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 5 (2000) 20-27
23. John A., and Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7 (2001) 14-23
24. Ferrero R., and Torres M. Prolonged exposure to YC-1 induces apoptosis in adreno-medullary endothelial and chromaffin cells through a cGMP-independent mechanism. Neuropharmacology 41 (2001) 895-906
25. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95 (2003) 516-525
26. Zhang Y., Griffith E.C., Sage J., Jacks T., and Liu J.O. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 97 (2000) 6427-6432
27. Yoshida T., Kaneko Y., Tsukamoto A., Han K., Ichinose M., and Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res 58 (1998) 3751-3756
28. Bhargava P., Marshall J.L., Rizvi N., Dahut W., Yoe J., Figuera M., et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5 (1999) 1989-1995